Evaluation of An Aerosolized Selective COX-2 Inhibitor as a Potentiator of Doxorubicin in a Non-Small-Cell Lung Cancer Cell Line

Author： Haynes Alfred Shaik Madhu Sudhan Chatterjee Abhijit Singh M.

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.20, Iss.9, 2003-09, pp. : 1485-1495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer

By Scagliotti Giorgio

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2855-2866

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E. Easthope Stephanie E.

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li de Boer Richard H

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for non-small-cell lung cancer

By Felip Enriqueta Santarpia Mariacarmela Rosell Rafael

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 3, 2007-09 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite

Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer

Current Medicinal Chemistry, Vol. 9, Iss. 21, 2002-11 ,pp. : 1851-1858

Bentham Science Publishers

Access to resources Recommend Favorite